SINGAPORE: MERCK (MRK.N) recently announced a collaboration with Asian micronation Singapore regarding an anti-viral medication targeting (SARS-CoV-2) or COVID-19, for short.
Although still experimental and new on the market, Molnupiravir is a unique oral medication tailored to initiate faults into the viral genetic code. Interim clinical trial data released recently is promising. It shows the drug in action, decreasing the risk of severe infection or hospitalization by up to 50 per cent.
Singapore’s neighbours, Malaysia and Thailand, are also looking into brokering the same deal. However, it isn’t just Asian countries rushing to purchase the patented drug. Australia has also signed an agreement for the miracle pill.